TY - JOUR
T1 - Zwitterionic Molecularly Imprinted Hairy Cellulose Nanocrystals Enable Selective Vancomycin Removal
AU - Koshani, Roya
AU - Yeh, Shang Lin
AU - Kheirabadi, Sina
AU - He, Zeming
AU - Park, Min Ju
AU - LeConey, Sean
AU - Read, Andrew F.
AU - Sheikhi, Amir
N1 - Publisher Copyright:
© 2025 American Chemical Society.
PY - 2025/4/8
Y1 - 2025/4/8
N2 - Access to free, off-target, and nontherapeutic doses of antibiotics is a key driving factor in the emergence of antimicrobial resistance (AMR). Intravenously (IV) administered vancomycin (VAN) is among the last-line antibiotics for treating infections caused by multidrug-resistant Gram-positive bacteria. A fraction of the total IV dose unwantedly reaches the gastrointestinal tract, driving AMR. Selective VAN removal from the complex intestinal fluid may reduce the probability of AMR emergence; however, it remains a significant challenge due to the competitive adsorption of other species. Here, we engineer novel VAN-imprinted polymerized zwitterionic hairy cellulose nanocrystals (ViPZ-HCNC) that selectively capture VAN with a removal capacity of ∼ 235 mg g-1 at an imprinting factor of ∼ 7.5. ViPZ-HCNC provide the first nanocellulose-based material with an excellent selectivity for VAN against lysine, lysozyme, and bovine serum albumin, which efficiently remove VAN from calcium ion-containing solutions and simulated intestinal fluids. Additionally, ViPZ-HCNC are not toxic against NIH/3T3 murine fibroblast cells. We envision that ViPZ-HCNC may pave the way for developing soft materials that selectively remove off-target VAN from a broad range of media, preventing VAN resistance evolution. This research is a step forward in addressing the long-lasting AMR challenge using a biobased platform.
AB - Access to free, off-target, and nontherapeutic doses of antibiotics is a key driving factor in the emergence of antimicrobial resistance (AMR). Intravenously (IV) administered vancomycin (VAN) is among the last-line antibiotics for treating infections caused by multidrug-resistant Gram-positive bacteria. A fraction of the total IV dose unwantedly reaches the gastrointestinal tract, driving AMR. Selective VAN removal from the complex intestinal fluid may reduce the probability of AMR emergence; however, it remains a significant challenge due to the competitive adsorption of other species. Here, we engineer novel VAN-imprinted polymerized zwitterionic hairy cellulose nanocrystals (ViPZ-HCNC) that selectively capture VAN with a removal capacity of ∼ 235 mg g-1 at an imprinting factor of ∼ 7.5. ViPZ-HCNC provide the first nanocellulose-based material with an excellent selectivity for VAN against lysine, lysozyme, and bovine serum albumin, which efficiently remove VAN from calcium ion-containing solutions and simulated intestinal fluids. Additionally, ViPZ-HCNC are not toxic against NIH/3T3 murine fibroblast cells. We envision that ViPZ-HCNC may pave the way for developing soft materials that selectively remove off-target VAN from a broad range of media, preventing VAN resistance evolution. This research is a step forward in addressing the long-lasting AMR challenge using a biobased platform.
UR - http://www.scopus.com/inward/record.url?scp=105002309159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105002309159&partnerID=8YFLogxK
U2 - 10.1021/acs.langmuir.4c04813
DO - 10.1021/acs.langmuir.4c04813
M3 - Article
C2 - 40162629
AN - SCOPUS:105002309159
SN - 0743-7463
VL - 41
SP - 8554
EP - 8564
JO - Langmuir
JF - Langmuir
IS - 13
ER -